Advanced Search

 

Study ID Status Title Patient Level Data
ITI105316 Completed Randomized, single blind, parallel study to compare the safety and efficacy of ARIXTRA to Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of components.
ITZ111682 Completed A Single Dose, Randomized Study to Assess the Relative Bioavailability of Two Formulations and Food Effect on GSK1265744 in Healthy Male and Female Subjects
KG2104940 Completed A double-blind, randomized, placebo-controlled, repeat dose study to compare the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 with GW869682 in subjects with type 2 diabetes mellitus
KG2105246 Completed A Randomized Open-label, Repeat Dose, Two Sequence Cross-Over Study to Determine the Effect of GSK189075 on the Pharmacokinetic Parameters of Metformin (Glucophage) in Subjects with Type 2 Diabetes Mellitus.
KG2105251 Completed An evaluation of the safety, tolerability, and pharmacodynamic effects of GSK189075 when administered with furosemide or hydrochlorothiazide
KG2105253 Completed An Evaluation of the Pharmacokinetics of a Single Oral Dose of GSK189075 in Patients with Varying Degrees of Renal Insufficiency Compared to Volunteers with Normal Renal Function
KG2105255 Completed A double-blind, randomized 12-week study to evaluate the safety and efficacy of GSK189075 tablets vs pioglitazone in treatment naive subjects with type 2 diabetes mellitus
KG2105264 Completed A Mass Balance Study to Investigate the Metabolic Disposition of a 400 mg Single, Oral Dose of GSK189075 in Healthy Male Subjects
KG2107489 Completed A Randomized, Double-blind, Placebo-Controlled, Cross-Over Trial to Investigate the Effect of GSK189075 on Cardiac Repolarization as Compared to Placebo and a Single Dose of Moxifloxacin in Healthy Adult Subjects
KG2107494 Completed An open label, single-sequence, repeat-dose study to investigate the effects of GSK189075 on the pharmacokinetics of an oral contraceptive pill when coadministered to healthy female volunteers
KG2108197 Completed An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK189075
KG2109799 Completed A Randomized, Placebo-Controlled, Double-Blind, Repeat Dose, Dose Escalation trial to Investigate the Safety, Tolerability and Pharmacokinetics of Supratherapeutic Doses of GSK189075 Administered for 3 Days in Healthy Volunteers
KG2110243 Completed A Two-Week, Randomized, Double-Blind, Repeat-Dose, Parallel-Group Study to Evaluate the Safety and Tolerability of Metformin > 2000mg Co-Administered with Either GSK189075 500mg BID or GSK 189075 750mg BID to Subjects with Type 2 Diabetes Mellitus
KG2110375 Completed A Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In The Treatment of Type 2 Diabetes Mellitus in Treatment-Naïve Subjects
KG219017 Completed A double blind, randomized, placebo controlled, single-dose escalation, first-time-in-human crossover study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of GSK189075A in healthy subjects and in subjects with type 2 diabetes mellitus
KGI107465 Completed A double-blind, randomized, single ascending dose escalation, placebo-controlled, crossover study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK189075 administered to subjects with type 1 diabetes mellitus
KGO105858 Completed A Double-Blind, Randomized, Placebo-controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 inhibitor
KGW108201 Completed An exploratory study to evaluate weight loss, body composition changes, food intake and urine glucose excretion in healthy obese subjects over 8 weeks of dosing with GSK189075, GW869682 versus placebo
KGW111057 Completed An open-label, randomized, single dose, crossover study to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of modified release formulations of GSK189075 in healthy volunteers
KGW111083 Completed A double-blind, randomized, 6-sequence, 3-period, crossover drug drug interaction study to evaluate the pharmacokinetics of Wellbutrin SR and GSK189075 when co-administered or administered alone in healthy male volunteers
KSP10003 Completed A Phase I, Open-Label Study of SB-715992 in Combination with Docetaxel in Patients with Advanced Solid Tumors.
KSP10004 Completed A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination with Capecitabine on an Every 21-Day Schedule in Subjects with Advanced Solid Tumors
KSP10014 Completed A Phase I, Open-Label, Dose-Escalation Study of the Safety and Tolerability of Ispinesib in Combination with Carboplatin on an Every 21-Day Schedule in Subjects with Advanced Solid Tumors.
KSP20001 Completed Phase II, Open Label Study of Ispinesib in Subjects with Advanced or Metastatic Breast Cancer
KSP20007 Completed A Phase II, Open-Label Study of Ispinesib in Subjects with Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer (NSCLC)

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.